Abstract
Meningiomas are the most common primary intracranial tumor in adults. However, to date, systemic coexpression analyses for meningiomas fail to explain its pathogenesis. The aim of the present study was to construct coexpression modules and identify potential biomarkers associated with meningioma progression. Weighted gene coexpression network analysis (WGCNA) was performed based on GSE43290, and module preservation was tested by GSE74385. Functional annotations were performed to analyze biological significance. Hub genes were selected for efficacy evaluations and correlation analyses using two independent cohorts. A total of 14 coexpression modules were identified, and module lightcyan was significantly associated with WHO grades. Functional enrichment analyses of module lightcyan were associated with tumor pathogenesis. The top 10 hub genes were extracted. Ten biomarkers, particularly AHCYL2, FGL2, and KCNMA1, were significantly related to grades and prognosis of meningioma. These findings not only construct coexpression modules leading to the better understanding of its pathogenesis but also provide potential biomarkers that represent specific on tumor grades and identify recurrence, predicting prognosis and progression of meningiomas.
Highlights
Meningiomas are the most common primary intracranial tumor in adults, accounting for over 35% of intracranial tumors [1]
Following preprocessing of the data, a total of 5,000 genes and 47 meningioma samples in the dataset GSE43290 were extracted for the analyses
Compared with the two studies of Weighted gene coexpression network analysis (WGCNA) on meningiomas [9, 10], the present study highlighted the significant module associated with meningioma grade and the extracted hub genes were further confirmed by independent cohorts, which improved the Dynamic tree cut
Summary
Meningiomas are the most common primary intracranial tumor in adults, accounting for over 35% of intracranial tumors [1]. According to the 2007 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS), meningiomas are classified into three grades including grade I, grade II, and grade III [2]. In the updated 2016 classification, brain invasion was added into the diagnostic criteria of atypical meningioma, WHO grade II [3]. Despite the combination of different treatments, including surgery, radiotherapy, and chemotherapy, grade II and III meningiomas remain aggressive and are coupled with a poor prognosis and higher mortality [5]. Personalized therapy options that are more urgently required, providing improved therapy outcomes and improve prognosis for patients with meningioma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
